With effect from 1 April 2024, the founders, Saskia and Dirk Biskup, acquired all shares in cecava. The company is a spin-out of the biotechnology company CeGaT GmbH also led by the Biskups. In 2018 cecava was originally founded as a joint venture by CeGaT GmbH and the international medical technology company B. Braun. Despite many years of trusting cooperation between CeGaT and B. Braun, it was now mutually decided to terminate the cooperation as both partners will pursue different strategic directions in the future. As a consequence, B. Braun has sold its shares in cecava and CeGaT GmbH to the owner family. The parties have agreed not to disclose the purchase price.
About B. Braun
B. Braun (Melsungen, Germany) is one of the world’s leading medical technology companies. With 63,000 employees, B. Braun is a reliable partner, develops intelligent solutions and sets pioneering standards to accelerate progress in healthcare. In 2023, B. Braun generated revenues of 8.8 billion euros.
About CeGaT and cecava
CeGaT (Tübingen, Germany) is a global provider of genetic analyses for a wide range of topics in medical practice, research and the pharmaceutical industry. Founded in Tübingen in 2009, the company combines the latest sequencing technology and medical expertise with the aim of identifying the genetic causes of diseases and supporting patients and their care.
About cecava
cecava (Tübingen, Germany) is a biopharmaceutical immuno-oncology company jointly founded in 2018 by CeGaT GmbH and B. Braun. The company name cecava stands for “Center for Cancer Vaccines”. The Tübingen-based company is dedicated to the development of individualized neoepitope-based cancer vaccines for the treatment of tumor diseases. For cecava’s therapeutic approach, the clinically most relevant neoepitopes are derived from patient-individual tumor mutations using the company’s proprietary in silico pipeline. The neoepitope peptides are synthesized, formulated into vaccines and injected into the skin of the respective patient. Through the vaccination, the power of the patient’s immune system is unleashed to recognize and destroy tumor cells presenting the neoepitopes on their surface. cecava is currently preparing the first clinical trials for several tumor indications in order to prove the efficacy of the treatment and obtain marketing authorization.
